Soliris (eculizumab) - Increased Risk Of Hemolysis Or Low Hemoglobin With Serogroup B Meningococcal Vaccination
SOLIRIS Recall Summary Patients taking SOLIRIS (eculizumab) who received a serogroup B meningococcal vaccine may face an increased risk of hemolysis (breakdown of red blood cells) or low hemoglobin levels. This safety concern affects SOLIRIS users across Canada. The recall was issued due to product safety risks associated with the combination of this medication and that specific vaccine.
- Reason
- Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2016-10-25
- Status
- Closed
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/6776c625-fead-489d-aab6-6080c9c59c36